BioLine RX LtdNASDAQ:BLRX
- LAST PRICE0.6399
- TODAY'S CHANGE (%)-0.0001 (-0.0156%)
- Bid / Lots0.6200/ 17
- Ask / Lots0.6399/ 2
- Open / Previous Close0.6223 / 0.6400
- Day Range
- 52 Week Range
- Volume48,913
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 8502 | 0.622 |
| 09:36 ET | 2350 | 0.622 |
| 09:38 ET | 4998 | 0.6399 |
| 09:39 ET | 415 | 0.622 |
| 09:41 ET | 200 | 0.636498 |
| 09:59 ET | 703 | 0.621 |
| 10:01 ET | 11191 | 0.6152 |
| 10:12 ET | 5115 | 0.630001 |
| 10:17 ET | 3201 | 0.62 |
| 10:32 ET | 150 | 0.62 |
| 10:37 ET | 1000 | 0.62 |
| 10:42 ET | 1000 | 0.625 |
| 10:46 ET | 700 | 0.6399 |
| 10:50 ET | 1000 | 0.63 |
| 10:51 ET | 2700 | 0.62 |
| 10:57 ET | 147 | 0.6399 |
| 11:00 ET | 250 | 0.6299 |
| 11:06 ET | 2500 | 0.6399 |
May 17, 2024
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification, from 5:00PM ET on Friday May 17, 2024 by Dow Jones
5:00PM ET on Friday May 17, 2024 by Dow Jones
May 6, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.6M | -0.7x | --- |
Dare Bioscience Inc | 48.8M | -1.6x | --- |
Dyadic International Inc | 48.2M | -6.2x | --- |
Kezar Life Sciences Inc | 55.7M | -0.5x | --- |
Kronos Bio Inc | 61.3M | -0.5x | --- |
Palatin Technologies Inc | 32.3M | -0.9x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.6M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.50 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 11.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
